Kailera Therapeutics, Inc.

NASDAQ:KLRA

Biotechnology

Healthcare
$11.79 +2.66%

+$0.51 today

Market cap
$1.53B
Beta
0.00
52W Low $18.50High $28.23

Volume 0.42M

Average 0.80M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$120.21M

FY 2025 · Annual

Investing Cash Flow

-$492.60M

FY 2025 · Annual

Financing Cash Flow

$598.66M

FY 2025 · Annual

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$149.0M
+ D&A$310.0K
+ Stock-Based Comp$10.9M
+ Deferred Tax$0
+ Working Capital$16.8M
+ Other Non-Cash$714.0K
= Operating Cash Flow-$120.2M
- Capex-$2.1M
= Free Cash Flow-$122.3M

Analysis

FY2025 free cash flow is -$122.3M. FCF conversion is 82.1% of net income. Operating cash flow was -$120.2M, with capex of -$2.1M. The largest bridge item is Working Capital at $16.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 4, 2026
8-KCurrent reportNov 4, 2026
3Initial statement of beneficial ownershipSep 9, 2026
4Statement of changes in beneficial ownershipSep 9, 2026
SC 13GSC 13G filingAug 14, 2026

Does KLRA generate free cash flow?

Kailera Therapeutics, Inc. (KLRA) generated -$122.30M of free cash flow in fiscal 2025.

How much operating cash flow does KLRA produce?

Operating cash flow was -$120.21M, before capital expenditures of $2.09M.